

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Brodalumab (Siliq)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as the following:
 - Phototherapy – 8 weeks
 - Systemic non-biologics for psoriasis – 6 weeks
 - Biologics – 12 weeks
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-Formulary **brodalumab (Siliq)** will be covered on the prescription drug benefit for when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient has failed an adequate trial^ of phototherapy (unless documented by prescriber phototherapy not appropriate)
 - Patient has failed an adequate trial^, or patient has an allergy or intolerance* to, at least 1 of the following (or contraindication to all):
 - Methotrexate
 - Acitretin
 - Cyclosporine
 - Patient has failed an adequate trial^, or patient has an allergy or intolerance* to all of the following:
 - Adalimumab product (criteria based)
 - Secukinumab (criteria based)
 - Ustekinumab (criteria based)
 - Guselkumab (criteria based)
 - Risankizumab-rzaa (criteria based)
 - Patient does NOT have a diagnosis of Crohn's disease
 - Prescriber has completed the Prescriber Certification for Siliq REMS

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **brodalumab (Siliq)** will be covered on the prescription drug benefit when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient has tried and failed, or patient has an allergy or intolerance* to all of the following:
 - Adalimumab product (criteria based)

kp.org

Revised: 06/13/24
Effective: 08/01/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Brodalumab (Siliq)

- Secukinumab (criteria based)
- Ustekinumab (criteria based)
- Guselkumab (criteria based)
- Risankizumab-rzaa (criteria based)
- Patient does NOT have a diagnosis of Crohn's disease
- Prescriber has completed the Prescriber Certification for Siliq REMS

kp.org

Revised: 06/13/24
Effective: 08/01/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest